IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
about
NKG2D ligands as therapeutic targetsIFN-γ Rα is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouseNKG2D Ligands in Tumor Immunity: Two Sides of a CoinMolecular mechanisms of MHC class I abnormalities and APM components in human tumors.Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancerLymphocytes in cancer development: polarization towards pro-tumor immunityRegulation of ligands for the NKG2D activating receptor.Oncogenic stress sensed by the immune system: role of natural killer cell receptorsCoronary artery disease from isolated non-H2-determined incompatibilities in transplanted mouse hearts.Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1.Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma.Cancer immunoediting by the innate immune system in the absence of adaptive immunity.Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance.Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.Activation of the JAK/STAT-1 signaling pathway by IFN-gamma can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG.Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNANKG2D ligands in tumor immunity.Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.Effect of NKG2D ligand expression on host immune responsesB7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors.Targeting NKG2D in tumor surveillance.Regulation of self-ligands for activating natural killer cell receptors.Advances in NKG2D ligand recognition and responses by NK cells.NKG2D signaling in cancer immunosurveillance.The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy.Cancer immunoediting of the NK group 2D ligand H60a.Inflammatory cytokine-mediated evasion of virus-induced tumors from NK cell control.The combination therapy of α-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice.Type I Interferons and Natural Killer Cell Regulation in Cancer.A dual function of NKG2D ligands in NK-cell activation.Studies on the antigenicity of the NKG2D ligand H60a in tumour cells.Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression.In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth.Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.New twist on the regulation of NKG2D ligand expression.Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity.Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases.
P2860
Q27014888-818E3BEB-0EC1-4F6F-9C28-8ABA8608CFDCQ27342843-C06F7AC8-FEFE-4512-9FA0-78B2245A0C69Q28083832-9A7FECE6-C445-41CD-B678-E116227D794BQ30319636-5BD39BCE-F647-4ED4-9342-1375B3120879Q30525394-B2AEE362-B7AA-471B-BD51-4B41336E64EDQ33520828-FA2CBBC8-7781-49A6-B998-E5F72B4BABFBQ33712435-1E9B5989-6E7B-4B7D-81F6-A188D7B4F43DQ34321457-2C02C94A-1D4C-4729-BFAF-954AAF763C59Q34473267-F922A910-3ABE-4034-906E-2F0FA4BCB22AQ34867060-7A631AC4-B77C-4CE5-B3B9-06A627B3A6A9Q35790198-98FDD140-1795-4919-8C98-37BD814C03B9Q36244004-36D99D4C-484A-4A77-A394-972A1114C755Q36278057-89B4C1AE-FFB0-467E-95E5-E3F8242DF95DQ36986947-DC576902-7F0B-4953-BCB4-43C2FCA7A73BQ37002810-18A8DD43-9F59-43CF-973E-696D75211D04Q37066149-23281E70-09E3-40D8-9721-11537EF39EC4Q37153929-8E6EC636-E678-4AD7-887A-0BEB7B0BEFB3Q37271077-6E8BD87B-CA9F-4482-B8F8-504D11346354Q37287179-1B7992F9-F83D-4357-BCA4-5AB3B6B278FAQ37375443-EDBB537A-D628-4972-A46A-B496CA212809Q37764003-A766DFE9-0B7B-4CC1-827C-4A925D774A53Q37923837-CA627303-3F96-485F-9640-5CFA5350D481Q38005176-A77C2C4D-2A54-42F1-81F4-B331D493C518Q38108820-E9346521-2B99-4528-BF94-315207D8578DQ38180339-D5F4F51A-AA0E-4E7B-BC90-E99FE293B4A9Q38194944-D9564FF4-14E5-4078-A601-B8F2AFE555E0Q38318217-3DBCBC3F-6751-4A4A-95FE-FCF1B1800849Q38546761-AB450E81-86EA-4831-BCF8-AFCC70CB415CQ39138817-363294AE-F284-4238-A36D-9BC4904C1850Q39192254-BF6BF345-67D3-4A4C-AAAB-CAD43D1A0AA0Q39241784-3D044F5C-7FB2-47E9-9EC7-BCB8BAE31A45Q39323944-3CAD4E72-A308-4A75-A510-BF67C1806FD4Q39570485-A93011BC-8296-40E2-AFEE-CF866F79FB41Q39629365-A7DD43C6-2E8E-4BE5-8280-DA8B003627DCQ39781532-FE604414-1C14-4948-A2E6-B8A3DBFC8E36Q39904227-11397E53-C501-42A9-95B3-EC917ED1E647Q41684097-7BAD3E79-FB76-4EC5-ADFC-C76D8ED0FA7FQ42136711-E55CDE13-FF9D-4DCB-B4C6-5955FB2DE5CDQ42544946-0D0C49C4-A55D-403A-8CEA-A9A00B95B088Q46884989-A0046A9A-F050-4ECD-8563-04D26D29E664
P2860
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
@en
type
label
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
@en
prefLabel
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
@en
P2093
P1476
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
@en
P2093
Jack D Bui
Leonidas N Carayannopoulos
Lewis L Lanier
Robert D Schreiber
Wayne M Yokoyama
P304
P356
10.4049/JIMMUNOL.176.2.905
P407
P577
2006-01-01T00:00:00Z